

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com

 Web:
 lktlabs.com

Product Information


Product ID 06845

CAS No. 96829-58-2

Chemical Name N-Formyl-L-leucine(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester

Synonym Orlipastat, Xenical

Formula $C_{29}H_{53}NO_5$ Formula Wt. 495.73 Melting Point 43°C Purity \geq 98% Solubility Soluble in DMSO or ethanol.



Bulk quanitites available upon request

Product ID	Size
O6845	100 mg
O6845	500 mg
O6845	1 g

Store Temp 4°C

Ship Temp Ambient

Description Orlistat is an inhibitor of fatty acid synthase that is clinically administered for its anti-obesity benefits. Orlistat is often used as a weight loss aid, although it also exhibits anticancer chemotherapeutic activity. In animal models of T cell lymphoma, orlistat increases levels of ROS, NO, caspase 3, Bcl-2, and p53, increasing life span and inhibiting tumor growth; similar results are found in animal models of colorectal carcinoma.

References Kant S, Kumar A, Singh SM. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta. 2014 Jan;1840(1):294-302. PMID: 24060750.

Chuang HY, Chang YF, Hwang JJ. Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal. Biomed Pharmacother. 2011 Jul;65(4):286-92. PMID: 21723078.

Halpern A, Pepe RB, Monegaglia AP, et al. Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients. J Obes. 2010;2010. pii: 602537. PMID: 20871858.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.